Metabolic flexibility and an unusual route for peptidoglycan muramic acid recycling in mycobacteria

This study reveals that *Mycobacterium tuberculosis* and *M. smegmatis* exhibit metabolic flexibility in peptidoglycan recycling by utilizing a previously undescribed pathway to incorporate 2-modified MurNAc that bypasses both the canonical *E. coli*-type and *Pseudomonas*-type mechanisms.

The Gist

Imagine a bacterial cell, like Mycobacterium tuberculosis (the germ that causes TB), as a busy construction site. To keep growing and dividing, it needs to constantly build and repair its outer wall, called the peptidoglycan. This wall is made of bricks (sugars) and mortar (peptides).

Usually, when bacteria run out of raw materials, they have two main ways to get more bricks:

1. The "Factory" Method (De Novo): They build new bricks from scratch using basic ingredients.
2. The "Recycling" Method: They take apart old, broken bricks from their own wall, clean them up, and reuse them.

For decades, scientists thought bacteria only had two types of recycling machines:

• The "E. coli" Machine: This machine takes a specific brick (MurNAc), strips off a protective coating, turns it into a different kind of brick (GlcNAc), and then reassembles it.
• The "Pseudomonas" Machine: This is a shortcut. It takes the MurNAc brick and reassembles it without changing its shape first.

The Big Surprise
The researchers in this paper discovered that Mycobacteria (the TB family) are doing something completely different. They found that these bacteria can recycle their wall bricks using a "Secret Third Machine" that no one knew existed.

Here is how they figured it out, using a fun analogy:

The "Spy Tag" Experiment

Imagine you want to see how a factory recycles its materials. You sneak in a special brick that has a glowing neon tag on it.

• If the factory uses the "E. coli" machine, the machine strips off the tag along with the protective coating, and the tag disappears.
• If the factory uses the "Pseudomonas" machine, the tag stays on, but this machine doesn't exist in TB bacteria (they lack the blueprints for it).

The Result: The researchers added these "neon-tagged" bricks to TB bacteria. They expected the tag to vanish. Instead, the bacteria glowed brightly. The bacteria had successfully taken the tagged brick, recycled it, and built it right back into their wall.

This was a mystery! How could they recycle a brick with a weird tag if they didn't have the "Pseudomonas" machine to handle it, and the "E. coli" machine usually destroys the tag?

The "Magic Shortcut" Discovery

The team realized the bacteria were using a new, unique recycling route.

Think of the recycling process like a train journey:

• The Old Route (E. coli): The train (the sugar) has to stop at two stations (Glucosamine and GlcNAc) to change its cargo before getting back on the main line.
• The New Route (Mycobacteria): The bacteria found a secret tunnel. They can take the weird, tagged brick and skip the "change cargo" stations entirely. They transform it directly into a usable form that fits back into the wall, keeping the "neon tag" intact the whole time.

Why Does This Matter?

1. It's a Superpower: This new recycling route makes the bacteria very flexible. Even if they are stressed, starving, or attacked by antibiotics, they can scavenge their own wall parts and keep building.
2. It's a Weakness: Because this "Secret Third Machine" is unique to these bacteria and doesn't exist in humans or other common bacteria, it could be a Achilles' heel. If scientists can figure out exactly how this machine works, they might be able to build a new drug that jams the gears. If you stop the recycling, the bacteria can't repair their walls when they are under attack, and they might die.

In a Nutshell

Scientists thought bacteria had two ways to recycle their cell walls. They discovered that the bacteria causing TB have a third, secret way to do it. This secret method is so efficient that it allows them to reuse special "tagged" materials that other bacteria can't handle. This discovery opens the door to finding new antibiotics that specifically target this secret recycling tunnel, potentially helping us fight drug-resistant TB.

Technical Summary

1. Problem Statement

Bacterial peptidoglycan (PG) biosynthesis is a validated antibiotic target, but bacteria can survive stress (e.g., host environment, antibiotics) by recycling cell wall components. Two major recycling pathways are known:

• E. coli-type: Converts (anhydro)MurNAc to GlcNAc-6-P and then to Glucosamine-6-P (GlcN-6-P) via the enzyme NagA, eventually feeding into central metabolism or de novo PG synthesis.
• Pseudomonas-type: Bypasses GlcNAc and GlcN intermediates, converting MurNAc directly to UDP-MurNAc via enzymes AmgK and MurU.

The Gap: Mycobacteria (including the pathogen Mycobacterium tuberculosis) encode homologs for E. coli-type enzymes (like NagA) but lack homologs for Pseudomonas-type enzymes (AmgK, MurU). Consequently, it was assumed they could not incorporate 2-modified MurNAc probes (which retain a chemical handle at the 2-position) because NagA would remove the 2-acetyl group, destroying the handle. However, researchers observed that mycobacteria could incorporate these probes, suggesting an unknown recycling mechanism.

2. Methodology

The study employed a multidisciplinary approach combining chemical biology, genetics, and mass spectrometry:

• Metabolic Labeling & Microscopy: Various mycobacterial species (M. smegmatis, M. tuberculosis, M. abscessus) and related actinomycetes were incubated with 2-alkyne-MurNAc (2-alkNAM) or 2-azide-MurNAc. Fluorescence was detected via Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) or tetrazine ligation to visualize cell surface incorporation.
• Mass Spectrometry (LC-MS): Bacterial sacculi were digested with lysozyme. The resulting muropeptides were analyzed via high-resolution LC-MS to determine if the alkyne handle from 2-alkNAM was present in isolated MurNAc and GlcNAc fragments.
• Genetic Manipulation (CRISPRi & Knockouts):
  • CRISPRi: Used to deplete essential genes (glmS, glmM, glmU, murA) in M. smegmatis using an anhydrotetracycline (ATC)-inducible system.
  • Gene Deletion: Generated a ΔmurQ mutant (lacking the MurNAc-6-P etherase) and a ΔmurA strain.
• Rescue Assays: Depleted or mutant strains were grown in the presence of exogenous MurNAc, GlcNAc, or 2-alkNAM to test if these sugars could bypass the metabolic block and restore growth.
• Phylogenetic Analysis: 16S rRNA sequencing was used to map the distribution of the labeling phenotype across the Mycobacteriales order.

3. Key Contributions & Results

A. Discovery of a Novel Recycling Phenotype

• Unexpected Incorporation: Despite lacking AmgK and MurU, M. smegmatis, M. tuberculosis, and M. abscessus successfully incorporated 2-alkNAM into their peptidoglycan.
• Localization: Labeling occurred at the poles and septa, sites of active cell envelope metabolism, similar to D-amino acid probes.
• Phylogenetic Scope: The phenotype was observed in the Mycobacteriaceae family but not in Arthrobacter or Microbacterium (which labeled with D-amino acids but not 2-alkNAM), suggesting a specific mechanism within mycobacteria.

B. Biochemical Evidence of Dual Pathways

• LC-MS Analysis: 2-alkNAM was found in both MurNAc and GlcNAc fractions of digested peptidoglycan.
• Surprising Modification: Some fragments contained the alkyne handle on the GlcNAc moiety while the MurNAc moiety retained the native N-glycolyl modification. This indicates that the 2-modified MurNAc is converted into a GlcNAc intermediate without losing the 2-position modification, bypassing the NagA deacetylation step.

C. Genetic Dissection of Pathways

The study utilized growth rescue experiments to map the entry points of recycled sugars:

1. E. coli-type Pathway (Unmodified MurNAc):

   • Exogenous unmodified MurNAc rescued growth of glmS-depleted (GlcN-6-P deficient) cells.
   • This rescue was lost in ΔmurQ strains, confirming that unmodified MurNAc enters via the classic MurQ $\to$ NagA $\to$ GlcN-6-P route.
   • Unmodified MurNAc did not rescue glmM or glmU depletion, indicating it requires these enzymes to convert to UDP-GlcNAc.

2. Novel "Mycobacteria-type" Pathway (2-Modified MurNAc):

   • 2-alkNAM rescued glmS depletion (though less efficiently than unmodified MurNAc).
   • Crucially, 2-alkNAM rescued glmM and glmU depletion, whereas unmodified MurNAc did not.
   • Interpretation: This implies 2-alkNAM is recycled into a GlcNAc intermediate downstream of GlmM/GlmU (likely directly into UDP-GlcNAc or a precursor that bypasses the GlmM/GlmU steps), or via a route that generates UDP-GlcNAc without requiring the standard GlmM/GlmU conversion of GlcN-6-P.
   • MurA Bypass: 2-alkNAM partially rescued murA depletion, suggesting a potential third route that bypasses the MurA step (converting UDP-GlcNAc to UDP-MurNAc), possibly feeding directly into UDP-MurNAc or a modified variant.

D. Proposed Model

The authors propose a "Mycobacteria-type" recycling pathway distinct from both E. coli and Pseudomonas models:

• Unmodified MurNAc: Primarily uses the E. coli-type route (MurQ $\to$ NagA $\to$ GlcN-6-P).
• 2-Modified MurNAc: Uses a unique route that likely involves an unidentified transporter and a lactyl etherase (distinct from MurQ) that converts MurNAc to a GlcNAc intermediate without removing the 2-acetyl/alkyne handle. This intermediate then enters the de novo pathway at a step that bypasses NagA, GlmM, and potentially MurA.

4. Significance

• Metabolic Flexibility: The study reveals that mycobacteria possess a previously undescribed metabolic flexibility, utilizing multiple parallel pathways to recycle cell wall sugars depending on the chemical structure of the substrate.
• Novel Vulnerability: Since this pathway is essential for survival under stress (e.g., in host macrophages or during antibiotic treatment) and is distinct from human metabolism, the enzymes mediating this "Mycobacteria-type" recycling represent novel therapeutic targets for treating tuberculosis and other mycobacterial infections.
• Chemical Biology Insight: The findings explain why 2-modified MurNAc probes work in mycobacteria despite the absence of AmgK/MurU, validating these probes as tools for studying cell wall dynamics in pathogens that lack the canonical Pseudomonas machinery.

In summary, the paper identifies a unique, non-canonical peptidoglycan recycling pathway in mycobacteria that allows them to assimilate modified MurNAc sugars, bypassing key enzymatic steps of the known E. coli and Pseudomonas pathways.